Pykus Therapeutics, Inc. was founded in 2016 by ophthalmology residents at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. The company's core mission is to innovate retinal surgeries, making them less painful and more successful. Pykus Therapeutics focuses on developing a dissolvable intraocular surgical device, aimed at improving outcomes for patients undergoing retinal surgery. Their market focus is on ophthalmology, specifically targeting retinal specialists and surgical centers.
Notable affiliated individuals include the co-founders who were residents at prestigious institutions. Pykus Therapeutics has garnered attention for its novel approach to retinal tamponade, a critical aspect of retinal surgery. The company’s key achievements include the development of their innovative dissolvable device, which has the potential to significantly impact the field of ophthalmology by reducing patient discomfort and improving surgical success rates.
